Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Leleu

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Leukemia|June 2, 2012
Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathwayS Xu, H Evans, C Buckle, et al.
Leukemia|April 24, 1999
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdesE Wattel, E Solary, X Leleu, et al.
La Revue De Medecine Interne|August 11, 2015
[Pomalidomide for multiple myeloma]G Fouquet, M Macro, O Decaux, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2005
Characterization of familial Waldenstrom's macroglobulinemiaS P Treon, Z R Hunter, A Aggarwal, et al.
Leukemia|October 25, 2016
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaS Manier, J T Powers, A Sacco, et al.
Leukemia|January 12, 2017
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa StudyH Ludwig, K Weisel, M T Petrucci, et al.
Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.
Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Leukemia|June 2, 2012
Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathwayS Xu, H Evans, C Buckle, et al.
Leukemia|April 24, 1999
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdesE Wattel, E Solary, X Leleu, et al.
La Revue De Medecine Interne|August 11, 2015
[Pomalidomide for multiple myeloma]G Fouquet, M Macro, O Decaux, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2005
Characterization of familial Waldenstrom's macroglobulinemiaS P Treon, Z R Hunter, A Aggarwal, et al.
Leukemia|October 25, 2016
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaS Manier, J T Powers, A Sacco, et al.
Leukemia|January 12, 2017
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa StudyH Ludwig, K Weisel, M T Petrucci, et al.
Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.
Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Pageof 6